Company
Hua Medicine
Headquarters: Shanghai, China
Employees: 146
CEO: Dr. Li Chen Ph.D.
Market Cap
HK$1.37 Billion
HKD as of Jan. 1, 2025
US$176.8 Million
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes. The company also offers Dorzagliatin in combination with Metformin that is in Phase I clinical trial. In addition, it provides Dorzagliatin in combination with Sitagliptin, Empagli, Pioglitazone, and Insulin for the treatment of Type 2 diabetes that is in pre-clinical stage. Further, the company is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia or PD-LID. The company was incorporated in 2011 and is headquartered in Shanghai, China.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Hua Medicine has the following listings and related stock indices.
Stock: HKEX: 2552 wb_incandescent